KERX Financial Facts

Loss before income taxes: -17.67M
Total research and development: 10.46M
See Full Income Statement

Total liabilities and stockholders' equity: -191.95M
Property, plant and equipment, net: 349K
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 5/8/14 *Est. EPS Growth Rate -133.3% *Last Qtr.
Average EPS % Beat Rate -86.0% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +6.2% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A -6.5% Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A +24.8% Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A 0% Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A +73.3% Details
3/11/13 Q412 -$0.09-$0.08 -$0.01N/AN/A N/A +88.4% Details
11/8/12 Q312 -$0.08-$0.07 -$0.01N/AN/A N/A +484.4% Details
8/7/12 Q212 -$0.02-$0.09 +$0.07N/AN/A N/A +648.6% Details
5/8/12 Q112 -$0.13-$0.12 -$0.01N/AN/A N/A +882.3% Details